The Impact of Psychobiotic Therapy on Anxiety and Depressive Symptoms in Patients with Post-COVID Syndrome—A Randomized, Double-Blind, Placebo-Controlled Trial
Aug 2026· Metabolites· Vol 16, pp. 594· 0 citations· 71 references
Medicine
TL;DR
Psychobiotic supplementation in individuals recovering from COVID-19 who exhibit anxiety and/or depressive symptoms led to mood improvement and a reduction in symptom severity, and it may serve as a supportive treatment.
Abstract
Background: Recovering from COVID-19 does not always lead to complete recovery, and many patients report symptoms of anxiety and depression. One potential mechanism behind these disorders is dysbiosis. The aim of this study was to evaluate the impact of psychobiotic therapy on the effectiveness of treating anxiety and depressive symptoms in individuals who had previously experienced COVID-19. Methods: This study was designed as a randomized, double-blind, placebo-controlled trial. A total of 62 participants were randomly allocated to one of two groups: a psychobiotic group (PG; 23 women, 9 men) receiving 3 × 109 CFU Lactobacillus helveticus and Bifidobacterium longum, or a control group (CG; 21 women, 9 men) receiving a placebo, for 6 weeks. Fifty-six participants finalized the study and were included in the analysis (28 per group). The severity of depressive and anxiety symptoms at baseline and after the intervention was assessed using validated self-assessment tools: the Hospital Anxiety and Depression Scale (HADS), the Generalized Anxiety Disorder 7-item scale (GAD-7), the Beck Depression Inventory (BDI), and the Hopkins Symptom Checklist (SCL-90). Additionally, the profile of selected short-chain fatty acids (SCFAs) in the stool was assessed. Results: Following the supplementation period, the PG showed significantly lower median levels of depression and anxiety compared to the CG, corresponding to a 57.2% reduction in anxiety severity (GAD-7) and a 50.9% reduction in depressive symptoms (BDI) (HADS—Depression and Anxiety, and GAD-7: p = 0.0001; BDI: p = 0.0003). Additionally, the prevalence of anxiety and depressive symptoms significantly decreased in the PG compared to the CG based on the HADS-A (p = 0.0044), GAD-7 (p = 0.0219), and BDI (p = 0.0011) scores. Among the measured SCFAs, only the butyric acid concentration in PG increased significantly during supplementation (baseline vs. follow-up—p = 0.0338) and was higher in PG than in CG at the study’s end (p = 0.0248). However, in the PG, changes in the concentrations of all analyzed acids correlated with a reduction in the severity of anxiety symptoms measured using the HADS-A. Conclusions: Psychobiotic supplementation in individuals recovering from COVID-19 who exhibit anxiety and/or depressive symptoms led to mood improvement and a reduction in symptom severity, and it may serve as a supportive treatment.
BACKGROUND
Depressive and anxiety symptoms are highly prevalent among patients with cancer and are associated with substantial reductions in quality of life. However, effective therapeutic options remain limited. Ayahuasca, a serotonergic psychedelic traditionally used in Amazonian ritual contexts, has shown rapid anti...
R. M. Maekawa, L. T. L. Guerra, Bianca Villanova et al.· Journal of Clinical Psychoph...· 0 citations
Objective: Anxious distress is associated with poor outcomes in the treatment of major depressive disorder (MDD). This exploratory post hoc analysis utilized data from a phase 3 study to investigate adjunctive lumateperone 42 mg efficacy in patients with MDD with inadequate antidepressant therapy (ADT) response and anx...
Gary S. Sachs, S. Durgam, W. Earley et al.· Journal of Clinical Psychiat...· 0 citations
Abstract Background Anxiety disorders are a major health burden and current treatment options yield unsatisfactory results. Psychedelics, such as lysergic acid diethylamide (LSD) that act via agonism on serotonin 2A receptors, have recently been shown to be effective in the treatment of anxiety symptoms. Aims & Objecti...
F. Holze, F. Müller, P. Gasser et al.· International Journal of Neu...· 0 citations
Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored.
In this study, a prosp...
Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al.· BMC Psychiatry· 0 citations
This study aimed to investigate the effects of the Cerebiome® probiotic supplement on mild to moderate insomnia symptoms associated with work-related stress. Using a randomized, placebo-controlled, double-blind, parallel design, adults aged 18-65 with mild to moderate insomnia symptoms but no diagnosis of mental disord...
S. Binda, N. Auclair-Ouellet, Ola Kassem et al.· Sleep Medicine· 0 citations
BACKGROUND
Multiple sclerosis (MS) is associated with neurochemical alterations, cognitive impairment, and patient-reported symptoms that substantially affect quality of life. Although self-acupressure has shown promise for symptom management, its effects on neuropeptides and cognition remain unclear. This study aimed...
Şeyma Demir Erbaş, Elif Gencer Sendur, Dilek Yılmaz et al.· Journal of Neuroscience Nurs...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.